A PBM Oligopoly: Three Companies Control 80% Of US Prescriptions – How Can We Fix It?

After two years of research, the Federal Trade Commission's recent interim report on Pharmacy Benefit Managers has authoritatively documented the multiple ways in which the three largest PBMs have contributed to the rising cost of drugs. This investigation has shown a spotlight on a list of questionable practices that have long been the subject of complaints from consumers, independent pharmacies, pharmaceutical manufacturers, employers and other stakeholders.